Vulvovaginal Candidiasis Treatment Market: Global Industry Analysis and Forecast (2023-2029) by Type, Drug Class, Route of Administration, Distribution Channel, and Region

Global Vulvovaginal Candidiasis Treatment Market size was valued at USD 1352.80 Million in 2022 and the total Vulvovaginal Candidiasis Treatment revenue is expected to grow at a CAGR of 5.25% from 2023 to 2029, reaching USD 1935.48 Million.

Vulvovaginal Candidiasis (VVC) is primarily caused by Candida albicans, although other Candida species or yeasts are expected to occasionally be responsible. It is estimated that about 75% of women will experience at least one episode of VVC, and 40% to 45% will have recurrent episodes during their lifetime. Vulvovaginitis, which refers to an infection in the vulva and vagina in women, commonly occurs in their reproductive age. A smaller percentage, around 10% to 20% of women, may experience complicated VVC, necessitating specialized diagnostic and therapeutic approaches. As a result, this factor significantly impacted the Vulvovaginal Candidiasis Treatment market growth during the forecast period.

The rising prevalence of Vulvovaginal Candidiasis among women, increasing risk of recurrent Vulvovaginal Candidiasis, driving the demand for new therapeutics for treatment, augmenting the Vulvovaginal Candidiasis treatment market's growth. In addition, the growing awareness of candidiasis infection among the target population and rising product innovation all across the world to cure candidiasis are expected to be the further factors driving the demand for new therapeutics. For instance, in September 2021, Cidara Therapeutics, Inc., presented new clinical and non-clinical data for its Rezafungin which is being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. Hence, such product innovation is expected to boost the Vulvovaginal Candidiasis treatment market growth.



To know about the Research Methodology :- Request Free Sample Report
Vulvovaginal Candidiasis Treatment Market Dynamics:
Increasing prevalence of Vulvovaginal candidiasis (VVC)

The increasing prevalence of VVC among women is expected to be the primary factor driving the vulvovaginal candidiasis treatment market growth. According to the MMR analysis, it is estimated that more than 75% of women throughout their reproductive age have a minimum of one episode/ circumstance of vulvovaginal candidiasis (VVC) and approximately half of the women have two or more episodes/occurrences. Approximately 138 million women all across the world are expected to affect by recurrent vulvovaginal candidiasis each year, resulting in a global prevalence of 3871 cases per 100,000 women.

As a result, improved treatment solutions to treat the conditions are on the rise due to the high prevalence rate of this condition, significant morbidity, and monetary costs of recurrent vulvovaginal candidiasis. 10% to 20% of women are expected to have complex VVC, necessitating specific diagnostic and treatment considerations. As a result, the increasing prevalence of vulvovaginal candidiasis among women is rising the demand for advanced treatment solutions such as oral and topical antifungal medications, thus driving the revenue growth of the vulvovaginal candidiasis treatment market throughout the forecast period.



Rising regulatory approvals

The rising regulatory approvals for the treatment of vulvovaginal candidiasis are expected to offer lucrative growth potentials for the vulvovaginal candidiasis treatment market players during the forecast period. Topical medications for the vulvovaginal candidiasis treatment have experienced a notable increase in regulatory approvals by various authorities such as the U.S. Food and Drug Administration (FDA), etc. according to the analysis, currently, the FDA has approved medications designed to address Mycovia, a pharmaceutical company specializing in antifungal treatments. These approved medications include oteseconazole, which is the first product from Mycovia to receive FDA approval.

Oteseconazole is categorized as an azole antifungal and is indicated for reducing the occurrence of Recurrent Vulvovaginal Candidiasis (RVVC). Additionally, ibrexafungerp tablets, marketed as Brexafemme, have also been approved by the FDA. Healthcare professionals commonly prescribe both oteseconazole and ibrexafungerp tablets (Brexafemme) for the treatment of vaginal yeast infections, including vulvovaginal candidiasis (VVC). These medications have gained significant popularity among medical practitioners for their effectiveness in addressing such infections.
Vulvovaginal Candidiasis Treatment Market Segment Analysis:
By type, the recurrent vulvovaginal candidiasis segment held the highest market share of over 45% and led the global vulvovaginal candidiasis treatment market in 2022. The segment is further expected to maintain its trends during the forecast period. Recurrent vulvovaginal candidiasis (RVVC) is a complicated form of vaginal yeast infection. It occurs in less than 5% of women but has a significant economic impact. Around 40-50% of VVC cases experience recurrent episodes. RVVC can be classified as idiopathic (with no known underlying causes) or secondary, which can be linked to factors like frequent antibiotic use, diabetes, or other host-related factors.

The underlying mechanisms of RVVC are not well understood, and most women with RVVC do not have identifiable predisposing conditions. Non-albicans Candida species like C. glabrata are found in 10-20% of women with recurrent VVC. Recurrent VVC can be associated with coexisting dermatological conditions such as lichen sclerosis and immunosuppression like HIV infection. The increasing prevalence of RVVC, the need for prolonged treatments, growing awareness, and the development of effective drugs are expected to drive the growth of this segment.

By drug class, the fluconazole segment dominated the global vulvovaginal candidiasis treatment market in 2022. Oral treatment with a single dose of fluconazole is effective for treating uncomplicated VVC. Treatment of complicated VVC is prolonged and most commonly consists of multiple doses of oral fluconazole. Thus increasing the need for fluconazole for treating VVC driving the segment growth. However, with the entry of BREXAFEMME and Mycovia in the space, Fluconazole's share is expected to decline by the end of the forecast period. Nevertheless, these novel drugs come with higher pricing, which could slow down their market penetration.

Antimycotic agent, Clotrimazole, was first registered under the brand name Canesten in Germany in 1973. Canesten is still among the leading brand for the treatment of vulvovaginal candidiasis. Later, external cream, internal vaginal cream, and soft capsule (soft ovule) were available. The industry has the presence of different formulations under different trade names, such as Abzorb, Candid-V, Mycoderm-C, Surfaz, Kansel, Imidil, Orasep OT, and Cloben.

By Route of Administration, the oral segment is expected to grow at a CAGR of 5.50% during the forecast period and hold the highest market share by 2029. The increasing prevalence of vaginal yeast infections, along with the rising awareness and diagnosis of the condition, is expected to increase the demand for effective treatment. Oral medicines are a common & convenient route of administration for azoles, with good bioavailability, and are increasingly used for anti-fungal drugs. As a result, these factors are expected to support the segment growth during the forecast period.

Oral fluconazole is the most common prescription drug recommended as treatment and maintenance

therapy. It is also effective as short-duration therapy in recurrent VVC cases. Recently, the FDA has approved two oral dosage regimes of VIVJOA (oteseconazole) to reduce incidences of recurrent VVC. Additionally, the convenience and effectiveness of oral medications contribute to their popularity among both patients and healthcare providers. The development and launch of more advanced and potent antifungal drugs further contribute to the growth of the segment and increase the revenue share of the vulvovaginal candidiasis treatment market during the forecast period.
Vulvovaginal Candidiasis Treatment Market Regional Insights:
North America led the global vulvovaginal candidiasis treatment market with the highest revenue share of over 40% in 2022. The region is expected to maintain its trends throughout the forecast period. The increasing target population of vulvovaginal candidiasis across the region is expected to be the primary growth factor driving the regional market growth. In addition, increasing awareness regarding vulvovaginal candidiasis among women, rising healthcare expenditures, availability of advanced therapeutic options, etc. are further contributing to the market growth.

The rising clinical trials and research and development activities in North America are expected to support the vulvovaginal candidiasis treatment market revenue growth. For example, In June 2021, the FDA granted authorization to BREXAFEMME, primarily for treating Vulvovaginal Candidiasis (VVC). On November 2022, the FDA approved its secondary use for preventing recurrent VVC. Additionally, ongoing late-stage clinical trials are investigating Ibrexafungerp's effectiveness in treating severe invasive fungal infections in hospitalized patients.

The U.S. is expected to lead the regional market by 2029 due to increasing research and product development activities, increasing patient population, governmental initiatives to increase awareness of the conditions, etc. According to the MMR analysis, around 149,934 women in the United States were diagnosed with Vulvovaginal Candidiasis (VVC) in April 2022, with 3.4% of them experiencing recurrent VVC (RVVC). The South census region had the highest VVC rate, standing at 14.3 cases per 1,000 female patients. This high prevalence of vaginal candidiasis is driving the demand for new therapeutics and contributing to the vulvovaginal candidiasis treatment market growth in the country.
Vulvovaginal Candidiasis Treatment Market Scope: Inquire before buying



Vulvovaginal Candidiasis Treatment Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
USD 1352.80 Million


Forecast Period 2023 to 2029 CAGR:
5.25 %
Market Size in 2029:
USD 1935.48 Million


 Segments Covered:
by Type
Acute Vulvovaginal Candidiasis
Recurrent Vulvovaginal Candidiasis
Severe Vulvovaginal Candidiasis
Non–albicans Vulvovaginal Candidiasis


by Drug Class
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others


by Route of Administration
Oral
Intravenous
Topical


by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy



Vulvovaginal Candidiasis Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Vulvovaginal Candidiasis Treatment Market Key Players:
1. Astellas Pharma Inc. (Japan)
2. Mycovia Pharmaceuticals, Inc. (United States)
3. Basilea Pharmaceutica Ltd. (Switzerland)
4. Scynexis, Inc. (United States)
5. Grupo Ferrer Internacional S.A. (Spain)
6. Cadila Pharmaceuticals (India)
7. Bristol-Myers Squibb Company (United States)
8. Mylan N.V. (United States)
9. Lupin Limited (India)
10. Sun Pharmaceutical Industries Ltd. (India)
11. Glenmark Pharmaceuticals Ltd. (India)
12. Cipla Limited (India)
13. Dr. Reddy's Laboratories Ltd. (India)
14. Aurobindo Pharma Limited (India)
15. Torrent Pharmaceuticals Ltd. (India)
16. Zydus Cadila (India)
17. Alembic Pharmaceuticals Limited (India)
18. Sandoz International GmbH (Switzerland)
19. Accord Healthcare Ltd. (United Kingdom)
20. Amneal Pharmaceuticals LLC (United States)

FAQs:

1. What are the growth drivers for the Vulvovaginal Candidiasis Treatment market?
Ans. The rising prevalence of Vulvovaginal Candidiasis among women and the increasing risk of recurrent Vulvovaginal Candidiasis is expected to be the major driver for the Vulvovaginal Candidiasis Treatment market.

2. What is the major restraint for the Vulvovaginal Candidiasis Treatment market growth?
Ans. Stringent government regulations are expected to be the major restraining factor for the Vulvovaginal Candidiasis Treatment market growth.

3. Which region is expected to lead the global Vulvovaginal Candidiasis Treatment market during the forecast period?
Ans. North America is expected to lead the global Vulvovaginal Candidiasis Treatment market during the forecast period.

4. What is the projected market size & growth rate of the Vulvovaginal Candidiasis Treatment Market?
Ans. The Global Vulvovaginal Candidiasis Treatment Market size was valued at USD 1352.80 Million in 2022 and the total Vulvovaginal Candidiasis Treatment revenue is expected to grow at a CAGR of 5.25% from 2023 to 2029, reaching nearly USD 1935.48 Million.

5. What segments are covered in the Vulvovaginal Candidiasis Treatment Market report?
Ans. The segments covered in the Vulvovaginal Candidiasis Treatment market report are Type, Drug Class, Route of Administration, Distribution Channel, and Region.